Filtern
Volltext vorhanden
- ja (18)
Gehört zur Bibliographie
- ja (18)
Dokumenttyp
Sprache
- Englisch (18)
Schlagworte
- B cells (2)
- BMP (2)
- BMP-2 (2)
- Bone morphogenetic protein-2 (2)
- bone regeneration (2)
- gene expression (2)
- growth factor beta (2)
- multiple myeloma (2)
- subcutaneous animal model (2)
- tissue engineering (2)
- Apoptosis (1)
- B cell receptors (1)
- BMP-2 delivery (1)
- Biocompatibility (1)
- Biodegradable polymer scaffolds (1)
- Bone tissue engineering (1)
- CYR61 (1)
- Cancer (1)
- Growth; BMP-2 (1)
- In-vitro (1)
- Mandibular continuity defects (1)
- Marrow stromal cells (1)
- Mechanisms (1)
- Mesenchymal transition (1)
- Microenvironment (1)
- Myofibroblast differentiation (1)
- Oral squamous cell carcinoma (1)
- Proliferation (1)
- Receptor (1)
- Sinus floor augmentation (1)
- Smooth-muscle-cells (1)
- Squamous-cell carcinoma (1)
- TGF-beta (1)
- TGFβ/BMP signaling (1)
- Tumorigenicity (1)
- animal model (1)
- antagonist (1)
- apoptosis (1)
- betaglycan (1)
- biocompatibility (1)
- biocompatible materials (1)
- bioconjugation (1)
- biological models (1)
- bone critical size defect (1)
- bone morphogenetic protein (1)
- bone morphogenetic protein 2 (BMP2) (1)
- bone morphogenetic protein 9 (BMP9) (1)
- bone morphogenetic proteins (1)
- brachtydacyly type A2 (1)
- cell binding (1)
- cell cycle and cell division (1)
- cell differentiation (1)
- cell metabolism (1)
- cell proliferation (1)
- clinical applications (1)
- collagen sponge (1)
- coreceptor (1)
- covalent coupling (1)
- cross-talk (1)
- cryostructured scaffolds (1)
- crystal structure (1)
- crystal-structure (1)
- differentiation (1)
- dominant-negative mutatio (1)
- fibroblast growth factor (1)
- functional initiators (1)
- gene encoding noggin (1)
- glycoprotein (1)
- growth and differentiation factor 5 (1)
- heparin binding sites (1)
- inflammation (1)
- interface (1)
- inflammatory response (1)
- iron metabolism (1)
- ligand binding (1)
- ligand-receptor complex (1)
- ligand-receptor promiscuity (1)
- membrane receptor signaling (1)
- metallo-supramolecular polymer (1)
- molecular mechanism (1)
- morphogenetic protein receptors (1)
- mutagenesis (1)
- necrotic cell death (1)
- osteochondral lesion (1)
- platelet-derived growth factor (1)
- polymerization (1)
- polypeptoids (1)
- postpolymerization modification (1)
- proteins (1)
- receptor type III (1)
- regenerative medicine (1)
- rhBMP–2 (1)
- ring-opening polymerization (1)
- signal integration (1)
- signal specification (1)
- signal tranduction (1)
- signal transduction (1)
- signaling (1)
- superfamily (1)
- translational research (1)
- weight-bearing (1)
Institut
- Lehrstuhl für Tissue Engineering und Regenerative Medizin (18)
- Julius-von-Sachs-Institut für Biowissenschaften (6)
- Theodor-Boveri-Institut für Biowissenschaften (4)
- Abteilung für Molekulare Innere Medizin (in der Medizinischen Klinik und Poliklinik II) (3)
- Klinik und Poliklinik für Mund-, Kiefer- und Plastische Gesichtschirurgie (3)
- Institut für Funktionsmaterialien und Biofabrikation (2)
- Institut für Organische Chemie (2)
- Abteilung für Funktionswerkstoffe der Medizin und der Zahnheilkunde (1)
- Augenklinik und Poliklinik (1)
- Klinik und Poliklinik für Allgemein-, Viszeral-, Gefäß- und Kinderchirurgie (Chirurgische Klinik I) (1)
Sonstige beteiligte Institutionen
EU-Projektnummer / Contract (GA) number
- 607051 (3)
- 242175-VascuBone (1)
- 242175‐VascuBone (1)
- 309962 (1)
- 723770 (1)
Addition of heparin binding sites strongly increases the bone forming capabilities of BMP9 in vivo
(2023)
Highlights
• Despite not being crucial for bone development BMP9 can induce bone growth in vivo.
• BMP9 induced bone formation is strongly enhanced by introduced heparin binding sites.
• BMP9s bone forming capabilities are triggered by extracellular matrix binding.
• Heparin binding BMP9 (BMP9 HB) can improve the current therapies in treating bone fractures.
Abstract
Bone Morphogenetic proteins (BMPs) like BMP2 and BMP7 have shown great potential in the treatment of severe bone defects. In recent in vitro studies, BMP9 revealed the highest osteogenic potential compared to other BMPs, possibly due to its unique signaling pathways that differs from other osteogenic BMPs. However, in vivo the bone forming capacity of BMP9-adsorbed scaffolds is not superior to BMP2 or BMP7. In silico analysis of the BMP9 protein sequence revealed that BMP9, in contrast to other osteogenic BMPs such as BMP2, completely lacks so-called heparin binding motifs that enable extracellular matrix (ECM) interactions which in general might be essential for the BMPs' osteogenic function. Therefore, we genetically engineered a new BMP9 variant by adding BMP2-derived heparin binding motifs to the N-terminal segment of BMP9′s mature part. The resulting protein (BMP9 HB) showed higher heparin binding affinity than BMP2, similar osteogenic activity in vitro and comparable binding affinities to BMPR-II and ALK1 compared to BMP9. However, remarkable differences were observed when BMP9 HB was adsorbed to collagen scaffolds and implanted subcutaneously in the dorsum of rats, showing a consistent and significant increase in bone volume and density compared to BMP2 and BMP9. Even at 10-fold lower BMP9 HB doses bone tissue formation was observed. This innovative approach of significantly enhancing the osteogenic properties of BMP9 simply by addition of ECM binding motifs, could constitute a valuable replacement to the commonly used BMPs. The possibility to use lower protein doses demonstrates BMP9 HB's high translational potential.